Insider Buying: Immunome, Inc. (NASDAQ:IMNM) CEO Buys 137,100 Shares of Stock

Immunome, Inc. (NASDAQ:IMNM) CEO Clay B. Siegall purchased 137,100 shares of Immunome stock in a transaction dated Wednesday, March 26th. The stock was bought at an average price of $7.29 per share, for a total transaction of $999,459.00. Following the completion of the transaction, the chief executive officer now directly owns 806,736 shares in the company, valued at $5,881,105.44. The trade was a 20.47 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Immunome Trading Down 4.0 %

Immunome stock opened at $6.99 on Friday. The company has a fifty day simple moving average of $9.50 and a 200 day simple moving average of $11.33. Immunome, Inc. has a 1-year low of $6.90 and a 1-year high of $24.87. The company has a market cap of $607.79 million, a P/E ratio of -0.86 and a beta of 1.93.

Immunome (NASDAQ:IMNM) last released its earnings results on Wednesday, March 19th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.16). Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. The company had revenue of $2.74 million during the quarter, compared to analyst estimates of $3.07 million. On average, equities research analysts forecast that Immunome, Inc. will post -2.21 EPS for the current year.

Institutional Investors Weigh In On Immunome

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. BNP Paribas Financial Markets acquired a new position in Immunome during the fourth quarter worth $70,000. KLP Kapitalforvaltning AS bought a new position in shares of Immunome in the 4th quarter valued at about $75,000. AlphaQuest LLC increased its stake in shares of Immunome by 786,700.0% during the 4th quarter. AlphaQuest LLC now owns 7,868 shares of the company’s stock worth $84,000 after purchasing an additional 7,867 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Immunome by 482.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company’s stock valued at $91,000 after purchasing an additional 7,129 shares during the period. Finally, Aquatic Capital Management LLC acquired a new stake in Immunome in the 4th quarter valued at about $95,000. Institutional investors own 44.58% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Lifesci Capital initiated coverage on Immunome in a report on Tuesday, March 11th. They set an “outperform” rating and a $20.00 target price on the stock. Stephens reaffirmed an “overweight” rating and set a $30.00 price target on shares of Immunome in a research report on Thursday, March 20th. Guggenheim cut their price target on shares of Immunome from $35.00 to $25.00 and set a “buy” rating on the stock in a research note on Thursday, March 20th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $33.00 target price on shares of Immunome in a research note on Thursday, March 20th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, Immunome presently has a consensus rating of “Buy” and a consensus price target of $25.50.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.